Expulsion of Immediate Postplacental Copper Intrauterine Devices at Six Months: A Prospective Cohort Study

Postpartum Clinical Trial

— PPIUD  

Official title:

Expulsion of Immediate Postplacental Copper Intrauterine Devices at Six Months: A Prospective Cohort Study (PPIUD)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02706340
• Other study ID #: 822078
• Status: Completed
• Start date: April 2015
• Est. completion date: July 2018

Study information

• Verified date: November 2018
• Source: University of Pennsylvania
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is an observational study enrolling women who have had a copper intrauterine device placed immediately after childbirth. The study follows participants for 6 month in order to evaluate the primary outcome of IUD expulsion within 6 months of delivery.

Description:

The purpose of the study is to measure the rate of expulsion of the copper intrauterine device (ParaGard®) when placed immediately after childbirth. Many women in the United States have unintended pregnancies. Long-acting reversible birth control methods, like the copper intrauterine device (IUD), help prevent unintended pregnancy. This is because, once in place, the copper IUD provides excellent pregnancy prevention, and women using it do not have to do anything extra to make sure it works (like taking a birth control pill every day, for example). The copper IUD is safe and well liked among women who use it. Around the world, women have been getting their IUD fitted right after childbirth for the past 20 years, and this practice has been shown to be safe. This service has been offered at HUP since early 2014. When the IUD is placed after birth, there is a chance that it could fall out, as the uterus shrinks back to its pre-pregnancy size. Women who get their IUD fitted right after childbirth will be observed, and describe the rate of IUD expulsion at 6 months postpartum. Factors associated with IUD expulsion will be noted. Adult pregnant women delivering at the Hospital of the University of Pennsylvania, desiring an immediate IUD, and willing to follow up 6 months after birth, will be eligible to participate.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 309
• Est. completion date: July 2018
• Est. primary completion date: July 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult woman age 18 years or more

• Pregnant, 24 weeks 0 days gestation or more OR who have had a delivery at 34 weeks 0 days gestation or more

• Anticipating a delivery at the Hospital of the University of Pennsylvania

• Desiring an immediate postplacental TCu380A IUD, OR who have given birth and received an immediate postplacental TCu380A IUD

• Able and willing to give consent in English

• Willing to follow up 6 months after delivery

Exclusion Criteria:

• Allergy or contraindication to TCu380A

• Known cervical cancer or carcinoma in situ

• History of undiagnosed abnormal vaginal bleeding prior to pregnancy

• Unwilling to follow up in the six months following delivery will be excluded

Additional exclusion criteria apply after delivery:

• Preterm delivery (33 weeks 6 days gestation or less at birth)

• Clinical diagnosis of chorioamnionitis or treatment for presumed chorioamnionitis

• No longer desiring immediate postplacental TCu380A placement

• Subjects aged less than 18 years

• Men are excluded by the nature of this women's health research.

Related Conditions & MeSH terms

• Intrauterine Devices, Copper
• Postpartum

Intervention

Other:
• No intervention - observational study only

Locations

Country	Name	City	State
United States	Hospital of the University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary objective is to measure the rate of expulsion of the copper intrauterine device (TCu380A, marketed as ParaGard®) when placed within 10 minutes of placental delivery among women delivering at the University of Pennsylvania.		6 months